A new era of treatment for elderly acute myeloid leukemia (AML) patients?
Hagop M. Kantarjian
The potential clinical implications of targeted therapies for DLBCL and why the situation is complex
Highlights from the International Symposium on Acute Leukemias (ISAL) 2017 in Munich
What has changed in AML treatment in the last 30 years?
Next-generation sequencing: a breakthrough in sequencing technology